Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee

 
 

2020health Report Value-based pricing: the wrong medicine for the nation?

  • 07.05.2013
  • Julia Manning & Barbara Arzymanow

This paper tries to explore the potential impact of introducing an additional pricing scheme for new medicines on patients, who are usually blissfully unaware of pricing negotiations. It takes the approach of asking what concerns would the public still have if a new system of “value-based pricing” were introduced, despite the negotiations and new promises to include patients further in deliberations.

Image

In no way do we seek to disparage the hard work undertaken by researchers, health economists and civil servants who have been tasked with trying to make ‘value- based pricing’ (VBP) work. Our purpose is twofold: to ensure that people have as rapid access as possible to new medicines in the UK, and to give the UK the best possible environment to continue to attract research and development across all life sciences.

 

This publication was not sponsored by any external organisation. The views expressed are those of the authors and they are responsible for the accuracy of the content.   

 

 

Impact:

• Feature in Financial Times
• Built on our previous VBP publcations with LSE (London School of Economics)
• In July 2013 it was announced that NICE would oversee pricing of medicines but no details of what aspects of VBP thinking will be included as yet available.
• In October 2013 the government announced the extension of the cancer drugs fund (CDF) [see also Cancer Networks report] which has improved access to drugs but is another temporary measure. Notably, all new cancer drugs assessed by NICE this year have been turned down and can only be accessed via an appeal to the CDF.

Press Release Government plans to change medicines pricing could make it harder for sick people to get treatment

2020health today publish a review from a patient’s perspective of the government’s plans to change the way medicines are priced. Julia Manning, CEO of 2020health said: “Patients are usually blissfully unaware of pricing negotiations but the Government’s new plans for pricing will politicise a formerly non-contentious issue.” read on Government plans to change medicines pricing could make it harder for sick people to get treatment